Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYunfei LvKCKuang ChenGWGongqiang Wu

Discussion

Loading...

Member takes

Overview

Multicenter analysis demonstrates efficacy and safety of glofitamab in aggressive B-cell lymphoma, indicating its potential as a treatment option.

Key Points

  • Glofitamab achieved a complete response rate of 46.5% in the cohort of 65 patients with relapsed or refractory aggressive B-cell lymphoma.
  • The overall response rate reached 67.4%, with median progression-free survival of 6.0 months and overall survival of 13.9 months.
  • Analysis involved a multicenter study collecting clinical data from patients treated with glofitamab-based regimens, identifying adverse events and efficacy outcomes.
  • Findings support glofitamab's role in treating high-risk aggressive B-cell lymphoma, with significant predictors for response warranting further study.

Cite This Study

Lv et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe3https://doi.org/10.1182/blood-2025-7253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study2025
  2. 2Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma2025
  5. 5Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma2025